




Instance: composition-en-68bcf84e560e25281fc234537e658487
InstanceOf: CompositionUvEpi
Title: "Composition for rilutek Package Leaflet"
Description:  "Composition for rilutek Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/96/010/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp68bcf84e560e25281fc234537e658487)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - rilutek"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What RILUTEK is and what it is used for </li>
<li>What you need to know before you take RILUTEK </li>
<li>How to take RILUTEK </li>
<li>Possible side effects </li>
<li>How to store RILUTEK </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What rilutek is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What rilutek is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What RILUTEK is </p>
<p>The active substance in RILUTEK is riluzole which acts on the nervous system. </p>
<p>What RILUTEK is used for </p>
<p>RILUTEK is used in patients with amyotrophic lateral sclerosis (ALS). </p>
<p>ALS is a form of motor neurone disease where attacks of the nerve cells responsible for sending 
instructions to the muscles lead to weakness, muscle waste and paralysis. </p>
<p>The destruction of nerve cells in motor neurone disease may be caused by too much glutamate (a 
chemical messenger) in the brain and spinal cord. RILUTEK stops the release of glutamate and this 
may help in preventing the nerve cells being damaged. </p>
<p>Please consult your doctor for more information about ALS and the reason why this medicine has been 
prescribed for you. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take rilutek"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take rilutek"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take RILUTEK 
- if you are allergic to riluzole or any of the other ingredients of this medicine (listed in section 
6), 
- if you have any liver disease or increased blood levels of some enzymes of the liver 
(transaminases), 
- if you are pregnant or breast-feeding. </p>
<p>Warnings and precautions 
Talk to your doctor before taking RILUTEK:</p>
<ul>
<li>if you have any liver problems: yellowing of your skin or the white of your eyes (jaundice), 
itching all over, feeling sick, being sick </li>
<li>if your kidneys are not working very well </li>
<li>if you have any fever: it may be due to a low number of white blood cells which can cause an 
increased risk of infection 
If any of the above applies to you, or if you are not sure, tell your doctor who will decide what to 
do. </li>
</ul>
<p>Children and adolescents 
If you are less than 18 years of age, the use of RILUTEK is not recommended because there is no 
information available in this population. </p>
<p>Other medicines and RILUTEK 
Tell your doctor if you are taking, have recently taken or might take any other medicines. </p>
<p>Pregnancy, breast-feeding and fertility 
You MUST NOT take RILUTEK if you are or think you may be pregnant, or if you are 
breast-feeding. </p>
<p>If you think you may be pregnant, or if you intend to breast-feed, ask your doctor for advice before 
taking RILUTEK. </p>
<p>Driving and using machines 
You can drive or use any tools or machines, unless you feel dizzy or lightheaded after taking this 
medicine. </p>
<p>RILUTEK contains sodium<br />
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium 
free . </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take rilutek"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take rilutek"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure.  </p>
<p>The recommended dose is one tablet, twice a day.<br />
The tablets should be taken by mouth, every 12 hours, at the same time of the day each day (e.g. in the 
morning and evening). </p>
<p>If you take more RILUTEK than you should </p>
<p>If you take too many tablets, contact your doctor or the nearest hospital emergency department 
immediately.  </p>
<p>If you forget to take RILUTEK </p>
<p>If you forget to take your tablet, leave out that dose completely and take the next tablet at the usual 
time. 
Do not take a double dose to make up for a forgotten tablet. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>IMPORTANT 
Tell your doctor immediately 
- if you experience any fever (increase in temperature) because RILUTEK may cause a decrease 
in the number of white blood cells. Your doctor may want to take a blood sample to check the 
number of white blood cells, which are important in fighting infections. </p>
<ul>
<li>
<p>if you experience any of the following symptoms: yellowing of your skin or the white of your 
eyes (jaundice), itching all over, feeling sick, being sick, as this may be signs of liver disease 
(hepatitis).Your doctor may do regular blood tests while you are taking RILUTEK to make sure 
that this does not occur. </p>
</li>
<li>
<p>if you experience cough or difficulties in breathing, as this may be a sign of lung disease (called 
interstitial lung disease).  </p>
</li>
</ul>
<p>Other side effects 
Very common side effects (may affect more than 1 in 10 people) of RILUTEK are:</p>
<ul>
<li>tiredness  </li>
<li>feeling sick  </li>
<li>increased blood levels of some enzymes of the liver (transaminases).  </li>
</ul>
<p>Common side effects (may affect up to 1 in 10 people) of RILUTEK are:</p>
<ul>
<li>dizziness </li>
<li>numbness or tingling of the mouth </li>
<li>vomiting </li>
<li>sleepiness </li>
<li>increase in heartbeat </li>
<li>diarrhoea </li>
<li>headache </li>
<li>abdominal pain </li>
<li>pain </li>
</ul>
<p>Uncommon side effects (may affect up to 1 in 100 people) of RILUTEK are:</p>
<ul>
<li>anaemia  </li>
<li>allergic reactions  </li>
<li>inflammation of the pancreas (pancreatitis).  </li>
</ul>
<p>Not known: frequency cannot be estimated from the available data 
- rash </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store rilutek"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store rilutek"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What RILUTEK contains </p>
<ul>
<li>The active substance is riluzole. </li>
<li>The other ingredients are: 
Core: anhydrous dibasic calcium phosphate, micro crystalline cellulose, anhydrous colloidal silica, 
magnesium stearate, croscarmellose sodium; 
Coating: hypromellose, macrogol 6000, titanium dioxide (E171). </li>
</ul>
<p>What RILUTEK looks like and content of the pack </p>
<p>The tablets are film-coated, capsule-shaped and white. Each tablet contains 50 mg of riluzole and is 
engraved with  RPR 202  on one side. 
RILUTEK is available in a pack of 56 tablets to be taken orally. </p>
<p>Marketing Authorisation Holder 
Sanofi Winthrop Industrie 
82 Avenue Raspail 
94250 Gentilly 
France </p>
<p>Manufacturer 
Opella Healthcare International SAS 
56, Route de Choisy 
60200 Compi gne 
France </p>
<p>For any information about this medicinal product, please contact the local representative of the 
Marketing Authorisation Holder. </p>
<p>Belgi /Belgique/ Belgien 
Sanofi Belgium 
T l/Tel: +32 (0)2 710 54 Lietuva 
Swixx Biopharma UAB 
Tel: +370 5 236 91 <br />
Swixx Biopharma EOOD 
 .: +359 (0)2 4942 Luxembourg/Luxemburg 
Sanofi Belgium<br />
T l/Tel: +32 (0)2 710 54 00 (Belgique/Belgien) </p>
<p>esk  republika 
Sanofi s.r.o. 
Tel: +420 233 086 Magyarorsz g 
SANOFI-AVENTIS Zrt. 
Tel.: +36 1 505 0Danmark 
Sanofi A/S 
Tlf: +45 45 16 70 Malta 
Sanofi S.r.l.<br />
Tel: +39 02 39394Deutschland 
Sanofi-Aventis Deutschland GmbH 
Tel: 0800 52 52 Tel. aus dem Ausland: +49 69 305 21 Nederland 
Sanofi B.V. 
Tel: +31 20 245 4Eesti 
Swixx Biopharma O<br />
Tel: +372 640 10 Norge 
sanofi-aventis Norge AS 
Tlf: +47 67 10 71 <br />
Sanofi-Aventis   AEBE 
 : +30 210 900 16  sterreich 
sanofi-aventis GmbH 
Tel: +43 1 80 185   0 </p>
<p>Espa a 
sanofi-aventis, S.A. 
Tel: +34 93 485 94 Polska 
sanofi-aventis Sp. z o.o. 
Tel.: +48 22 280 00 France 
Sanofi Winthrop Industrie 
T l : 0 800 222 Appel depuis l tranger : +33 1 57 63 23 Portugal 
Sanofi - Produtos Farmac uticos, Lda. 
Tel: +351 21 35 89 Hrvatska 
Swixx Biopharma d.o.o. 
Tel: +385 1 2078 Rom nia 
Sanofi Romania SRL 
Tel: +40 (0) 21 317 31 Ireland 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +353 (0) 1 403 56 Slovenija 
Swixx Biopharma d.o.o. 
Tel: +386 1 235 51  sland 
Vistor hf. 
S mi: +354 535 7Slovensk  republika 
Swixx Biopharma s.r.o. 
Tel: +421 2 208 33 Italia 
Sanofi S.r.l.<br />
Tel:  800 536Suomi/Finland 
Sanofi Oy 
Puh/Tel: +358 (0) 201 200 <br />
C.A. Papaellinas Ltd. 
 : +357 22 741Sverige 
Sanofi AB 
Tel: +46 (0)8 634 50 Latvija 
Swixx Biopharma SIA 
Tel: +371 6 616 47 United Kingdom (Northern Ireland) 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +44 (0) 800 035 2This leaflet was last approved in {MM/YYYY}. </p> </div>"""      



Instance: composition-da-68bcf84e560e25281fc234537e658487
InstanceOf: CompositionUvEpi
Title: "Composition for rilutek Package Leaflet"
Description:  "Composition for rilutek Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/96/010/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp68bcf84e560e25281fc234537e658487)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - rilutek"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at tage Rilutek 
3. Sådan skal du tage Rilutek 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p> </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad Riluteker 
Det aktive indholdsstof i Riluteker riluzol, som virker på nervesystemet. </p>
<p>Hvad Rilutekanvendes til 
Rilutekanvendes til patienter med amyotrofisk lateral sclerose (ALS). </p>
<p>ALS er en form for motor-neuronsygdom, hvor angreb på de nerveceller, der er ansvarlige for at sende 
instruktioner til musklerne, fører til muskelsvaghed, muskeltab og lammelse. </p>
<p>Ødelæggelsen af nervecellerne i motor-neuronsygdomme kan skyldes for meget glutamat (et kemisk 
stof) i hjernen og rygmarven. Rilutek forhindrer frigivelsen af glutamat og dette kan hjælpe med at 
forebygge, at nerveceller bliver ødelagt.<br />
Få mere information hos din læge om ALS, og hvorfor du får denne medicin </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  rilutek"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  rilutek"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Rilutek 
- hvis du er allergisk over for riluzol eller et af de øvrige indholdsstoffer i Rilutek (angivet i 
punkt 6). 
- hvis du har en leversygdom eller forhøjede niveauer af visse lever-enzymer (aminotransferaser) 
i blodet. 
- hvis du er gravid eller ammer. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, før du tager Rilutek:</p>
<ul>
<li>hvis du har nogen form for leverproblemer: gulfarvning af huden eller det hvide i dine øjne 
(gulsot), kløe over det hele, føler dig syg, er syg. </li>
<li>hvis dine nyrer ikke fungerer normalt. </li>
<li>hvis du får feber. Dette kan være et tegn på et fald i antallet af hvide blodlegemer, som kan 
medføre forøget risiko for infektion. 
Hvis du oplever noget af ovenstående, eller hvis du føler dig usikker, så fortæl det til din læge, 
som vil beslutte, hvad der skal gøres. </li>
</ul>
<p>Børn og unge<br />
Hvis du er under 18 år, anbefales det ikke, at du tager Rilutek, da der ikke er nogen information 
tilgængelig for denne patientgruppe. </p>
<p>Brug af anden medicin sammen med Rilutek 
Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig. </p>
<p>Graviditet, amning og frugtbarhed 
Du må ikke tage Rilutek, hvis du er gravid eller ammer, eller har mistanke om, at du er gravid. </p>
<p>Hvis du har mistanke om, du er gravid, eller hvis du overvejer at amme, skal du diskutere det med din 
læge.  </p>
<p>Trafik- og arbejdssikkerhed 
Du kan køre bil og anvende værktøj og maskiner, når du tager Rilutek, medmindre du føler dig 
svimmel eller omtåget. </p>
<p>Rilutek indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. dosisenhed, dvs. det er i det 
væsentlige natriumfrit. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage rilutek"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage rilutek"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Den anbefalede dosis er 1 tablet to gange om dagen.<br />
Du skal indtage tabletterne oralt hver 12. time, på samme tidspunkt af dagen hver dag (for eksempel 
om morgenen og om aftenen). </p>
<p>Hvis du har taget for mange Rilutek 
Hvis du har taget for mange tabletter, skal du straks kontakte læge eller skadestue. </p>
<p>Hvis du har glemt at tage Rilutek 
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.  </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>VIGTIGT 
Kontakt straks din læge 
- Hvis du får nogen form for feber (forhøjet temperatur), da Rilutek kan medføre nedsættelse af 
antallet af hvide blodlegemer. Din læge kan ønske at tage blodprøver for at kontrollere antallet 
af hvide blodlegemer, som er vigtige for at kunne bekæmpe infektioner. </p>
<ul>
<li>
<p>Hvis du får nogen af følgende symptomer: Gulfarvning af huden eller det hvide i øjnene 
(gulsot), kløe over hele kroppen, du føler dig syg, eller kaster op, da dette kan være tegn på 
leverbetændelse (hepatitis). Din læge kan udføre regelmæssige blodprøver, mens du får 
Rilutek, for at sikre sig, at dette ikke sker. </p>
</li>
<li>
<p>Hvis du får hoste eller besvær med at trække vejret, da dette kan være tegn på en lungesygdom 
(som hedder interstitiel lungesygdom). </p>
</li>
</ul>
<p>Andre bivirkninger 
Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer) af Riluteker:</p>
<ul>
<li>Træthed </li>
<li>Kvalme </li>
<li>Forføjet niveau af nogle enzymer (aminotransferaser) i blodet. </li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer) af Riluteker:</p>
<ul>
<li>Svimmelhed </li>
<li>Prikken i munden </li>
<li>Opkastning </li>
<li>Søvnighed </li>
<li>Hurtigere hjerterytme </li>
<li>Diarré </li>
<li>Hovedpine </li>
<li>Mavesmerter </li>
<li>Smerter. </li>
</ul>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) af Riluteker:</p>
<ul>
<li>Blodmangel </li>
<li>Allergiske reaktioner </li>
<li>Betændelse i bugspytkirtlen (pancreatitis). </li>
</ul>
<p>Ikke kendt (kan ikke estimeres ud fra forhåndenværende data):</p>
<ul>
<li>Udslæt. </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter Exp. Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige opbevaringsbetingelser. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Rilutek indeholder 
- Aktivt stof: Riluzol. 
- Øvrige indholdsstoffer: 
Kerne: vandfri calciumphosphat, mikrokrystallinsk cellulose, vandfri kolloid silica, magnesiumstearat, 
samt croscarmellosenatrium. 
Overtræk: hypromellose, macrogol 6000 og titandioxid (E171). </p>
<p>Udseende og pakningsstørrelser 
Tabletterne er filmovertrukne, kapselformede og hvide. Hver tablet indeholder 50 mg riluzol og har 
"RPR 202" præget på den ene side af tabletten. 
Rilutek fås i en pakning af 56 tabletter til oral anvendelse. </p>
<p>Indehaver af markedsføringstilladelsen 
Sanofi Winthrop Industrie 
82 Avenue Raspail 
94250 Gentilly 
Frankrig </p>
<p>Fremstiller 
Opella Healthcare International SAS 
56, Route de Choisy<br />
60200 Compiègne 
Frankrig </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/ Belgien 
Sanofi Belgium 
Tél/Tel: +32 (0)2 710 54<br />
Lietuva 
Swixx Biopharma UAB 
Tel: +370 5 236 91<br />
България 
Swixx Biopharma EOOD 
Тел.: +359 (0)2 4942<br />
Luxembourg/Luxemburg 
Sanofi Belgium<br />
Tél/Tel: +32 (0)2 710 54 00 (Belgique/Belgien) </p>
<p>Česká republika 
Sanofi s.r.o. 
Tel: +420 233 086<br />
Magyarország 
SANOFI-AVENTIS Zrt. 
Tel.: +36 1 505 0 
Danmark 
Sanofi A/S 
Tlf: +45 45 16 70<br />
Malta 
Sanofi S.r.l. 
Tel: +39 02 39394Deutschland 
Sanofi-Aventis Deutschland gmbh 
Tel: +49 (0)180 52 52 Tel. aus dem Ausland: +49 69 305 21<br />
Nederland 
Sanofi B.V. 
Tel: +31 20 245 4 
Eesti 
Swixx Biopharma OÜ<br />
Tel: +372 640 10<br />
Norge 
Sanofi-aventis Norge AS 
Tlf: +47 67 10 71<br />
Ελλάδα 
Sanofi-Aventis Μονοπρόσωπη AEBE 
Τηλ: +30 210 900 16<br />
Österreich 
Sanofi-aventis gmbh 
Tel: +43 1 80 185 - 0 </p>
<p>España 
Sanofi-aventis, S.A. 
Tel: +34 93 485 94<br />
Polska 
Sanofi-aventis Sp. Z o.o. 
Tel.: +48 22 280 00<br />
France 
Sanofi Winthrop Industrie 
Tél : 0 800 222 Appel depuis l’étranger : +33 1 57 63 23<br />
Portugal 
Sanofi - Produtos Farmacêuticos, Lda. 
Tel: +351 21 35 89<br />
Hrvatska 
Swixx Biopharma d.o.o. 
Tel: +385 1 2078<br />
România 
Sanofi Romania SRL 
Tel: +40 (0) 21 317 31<br />
Ireland 
Sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +353 (0) 1 403 56<br />
Slovenija 
Swixx Biopharma d.o.o.<br />
Tel: +386 1 235 51<br />
Ísland 
Vistor hf. 
Sími: +354 535 7 
Slovenská republika 
Swixx Biopharma s.r.o. 
Tel: +421 2 208 33<br />
Italia 
Sanofi S.r.l. 
Tel: 800 536 
Suomi/Finland 
Sanofi Oy 
Puh/Tel: +358 (0) 201 200<br />
Κύπρος 
C.A. Papaellinas Ltd. 
Τηλ: +357 22 741 
Sverige 
Sanofi AB 
Tel: +46 (0)8 634 50<br />
Latvija<br />
Swixx Biopharma SIA<br />
Tel: +371 6 616 47<br />
United Kingdom (Northern Ireland) 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +44 (0) 800 035 2 </p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ} </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-68bcf84e560e25281fc234537e658487
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for rilutek Package Leaflet for language en"
Description: "ePI document Bundle for rilutek Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-68bcf84e560e25281fc234537e658487"
* entry[0].resource = composition-en-68bcf84e560e25281fc234537e658487

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp68bcf84e560e25281fc234537e658487"
* entry[=].resource = mp68bcf84e560e25281fc234537e658487
                            
                    
Instance: bundlepackageleaflet-da-68bcf84e560e25281fc234537e658487
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for rilutek Package Leaflet for language da"
Description: "ePI document Bundle for rilutek Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-68bcf84e560e25281fc234537e658487"
* entry[0].resource = composition-da-68bcf84e560e25281fc234537e658487

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp68bcf84e560e25281fc234537e658487"
* entry[=].resource = mp68bcf84e560e25281fc234537e658487
                            
                    



Instance: mp68bcf84e560e25281fc234537e658487
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product RILUTEK 50 mg film-coated tablets"
Description: "RILUTEK 50 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/96/010/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "RILUTEK 50 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 68bcf84e560e25281fc234537e658487ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "rilutek"

* status = #current
* mode = #working

* title = "List of all ePIs associated with rilutek"

* subject = Reference(mp68bcf84e560e25281fc234537e658487)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#rilutek "rilutek"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-68bcf84e560e25281fc234537e658487) // rilutek en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-68bcf84e560e25281fc234537e658487) // rilutek da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-68bcf84e560e25281fc234537e658487
InstanceOf: List

* insert 68bcf84e560e25281fc234537e658487ListRuleset
    